Speakers from Touchstone Exploration, Shanta Gold, Savannah Resources and Kavango Resources feature in our Natural Resources webinar on May 25th. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7,735.00
Bid: 7,728.00
Ask: 7,730.00
Change: 55.00 (0.72%)
Spread: 2.00 (0.03%)
Open: 7,682.00
High: 7,745.00
Low: 7,673.00
Yest. Close: 7,680.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

TOP NEWS: AstraZeneca Doses First Patient In Covid-19 Treatment Trial

Tue, 25th Aug 2020 07:58

(Alliance News) - Anglo-Swedish drugmaker AstraZeneca PLC on Tuesday said the first patients have now been dosed in its phase one trial of Covid-19 treatment, AZD7442.

The trial, named NCT04507256, will evaluate AZD7442's safety, tolerability, and pharmacokinetics. Pharmacokinetics describes the movement of a treatment into the body, as well as through and out of the body.

AZD7442 is a combination of two monoclonal antibodies and is being developed for the development and treatment of Covid-19. These antibodies are derived from convalescent patients infected with SARS-CoV-2 and were discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June.

Astra then optimised the antibodies, extending their half-life so as to "afford at least six months of protection from Covid-19".

If AZD7442 proves to be tolerated and has a "favourable safety profile" in the NCT04507256 trial then Astra will move to larger late-stage phase 2 and phase 3 trials. These later trials will evaluate AZD7442's efficacy as a possible preventative and treatment approach against the virus.

The trial will include as many as 48 healthy participants in the UK aged between 18 and 55. It is funded by the Defense Advanced Research Projects Agency, part of the US US Department of Defense, as well as the Biomedical Advanced Research and Development Authority. BARDA is part of the Office of the Assistant Secretary for Preparedness & Response at the US Department of Health & Human Services.

Mene Pangalos, executive vice president of BioPharmaceuticals Research & Development, said: "This trial is an important milestone in the development of our monoclonal antibody combination to prevent or treat Covid-19. This combination of antibodies, coupled to our proprietary half-life extension technology, has the potential to improve both the effectiveness and durability of use in addition to reducing the likelihood of viral resistance."

Alongside the antibody treatment, Astra is also developing a vaccine for Covid-19 with the University of Oxford. This vaccine would aim to prevent Covid-19 infection. In July, interim results from an ongoing phase 1/2 trial of vaccine AZD1222 were published showing it to be tolerated and able to generate robust immune responses against the virus in all evaluated participants. Phase 2/3 trials are ongoing with late-stage trial results expected later in 2020.

On Monday, the UK Government said it struck a deal with AstraZeneca to get "first access" to a vaccine once approved.

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News

Sri Lanka approves Pfizer COVID vaccine for emergency use

By Waruna KarunatilakeCOLOMBO, May 8 (Reuters) - Sri Lanka on Saturday approved Pfizer's COVID-19 vaccine for emergency use in Sri Lanka, as the island nation battles a third wave of the virus, while suffering a restricted supply of vaccines from ...

8 May 21 09:33

Britain free of coronavirus by August, outgoing vaccine task force chief says -Telegraph

May 7 (Reuters) - The new coronavirus will no longer be circulating in Britain by August, the government's departing vaccine taskforce chief Clive Dix told the Daily Telegraph on Friday."Sometime in August, we will have no circulating virus in th...

8 May 21 00:15

UPDATE 1-AstraZeneca weighs seeking full U.S. approval for COVID shot - WSJ

(Adds background related to AstraZeneca vaccine)May 7 (Reuters) - AstraZeneca Plc may skip asking the U.S. Food and Drug Administration for emergency-use authorization for its COVID-19 vaccine and instead pursue the more time-intensive application...

7 May 21 23:23

UPDATE 2-AstraZeneca weighs seeking full, not emergency, U.S. approval for COVID-19 shot - WSJ

(Adds response from AstraZeneca in paragraphs 3 and 4)May 7 (Reuters) - AstraZeneca Plc may skip asking the U.S. Food and Drug Administration for emergency-use authorization for its COVID-19 vaccine and instead pursue the more time-intensive appli...

7 May 21 23:23

AstraZeneca weighs seeking full U.S. approval for COVID-19 shot -WSJ

May 7 (Reuters) - AstraZeneca Plc may skip asking the U.S. Food and Drug Administration for emergency-use authorization for its COVID-19 vaccine, and instead pursue the more time-intensive application for a full-fledged license to sell the shot, ...

7 May 21 22:52

INSIGHT-How the U.S. locked up vaccine materials other nations urgently need

By Allison Martell and Euan RochaMay 7 (Reuters) - To fight the pandemic at home, the United States gave its own vaccine manufacturers priority access to American-made materials needed to make the shots.As a result, the U.S. government laid claim n...

7 May 21 16:00

WRAPUP 1-Britain, Germany in role reversal on AstraZeneca vaccine risks

* Britain restricts AstraZeneca to people aged over 40* In Germany, all adults free to get AZ shot on doctor's advice* Germany, with eye on summer hols, shortens gap between doses* EU regulator looking at AZ on reports of neurological illnessBy Al...

7 May 21 15:34

UPDATE 1-Vietnam reports first death in patient who received AstraZeneca COVID-19 vaccine

(Adds details and background)By Khanh VuHANOI, May 7 (Reuters) - Vietnam's health ministry on Friday reported its first death in a patient who received AstraZeneca's COVID-19 vaccine shot, as the country is battling a new outbreak.A 35-year-old fe...

7 May 21 15:31

Vietnam reports first death in patient who received AstraZeneca COVID-19 vaccine

HANOI, May 7 (Reuters) - Vietnam's health ministry on Friday reported its first death in a patient who received AstraZeneca's COVID-19 vaccine shot.A 35-year-old female health worker in the southern province of An Giang died on Friday, one day aft...

7 May 21 14:54

UPDATE 1-EU regulator reviews reports of rare nerve disorder after AstraZeneca shot

(Adds details from EMA statement on other vaccines, background)May 7 (Reuters) - Europe's medicines regulator said on Friday it was reviewing reports of a rare nerve-degenerating disorder in people who have received AstraZeneca's COVID-19 vaccine,...

7 May 21 13:15

UPDATE 2-EU reviews reports of rare nerve disorder after AstraZeneca's COVID-19 shot

* EMA reviewing AstraZeneca vaccine for Guillain-Barre syndrome* Rare nerve syndrome also linked some vaccinations in past* EMA also assessing heart inflammation with Pfizer, Moderna shots* Studies into possible links to rare blood clots ongoing (...

7 May 21 13:15

UPDATE 3-EU reviews reports of rare nerve disorder after AstraZeneca's COVID-19 shot

* EMA reviews AstraZeneca shot for Guillain-Barre syndrome* Rare nerve syndrome also linked some vaccinations in past* EMA assessing heart inflammation with Pfizer, Moderna shots* Studies into possible links to rare blood clots ongoing (Adds BioNTe...

7 May 21 13:15

Canada willing to discuss COVID-19 vaccine IP waiver -statement

OTTAWA, May 7 (Reuters) - Canada on Friday said that it was ready to discuss an intellectual property rights (IP) waiver for COVID-19 vaccines while it also recognized the importance of protecting IP and the integral role industry played in devel...

7 May 21 13:00

UPDATE 1-German panel to recommend J&J COVID vaccine for over-60s - Spiegel

(Adds RKI comment, background)BERLIN, May 7 (Reuters) - Germany's vaccine committee, known as STIKO, plans to recommend Johnson & Johnson's COVID-19 vaccine only for people over the age of 60, German magazine Der Spiegel reported on Friday, citing...

7 May 21 12:24

Germany's STIKO to recommend J&J COVID vaccine for over-60s - Spiegel

BERLIN, May 7 (Reuters) - Germany's vaccine committee, known as STIKO, plans to recommend Johnson & Johnson's COVID-19 vaccine only for people over the age of 60, German magazine Der Spiegel reported on Friday, citing no sources.Europe's drug regu...

7 May 21 11:58

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.